MDGL
Madrigal Pharmaceuticals, Inc.
526.39
1 x 538.33
1 x 538.00
bid
ask
-
13.50
2.50%
03:43 PM
timesize
| Ytd | -9.61% | |
| 1y | 80.38% |
523.92
day range
543.78
265.00
52 week range
615.00
| Open | 540.56 | Prev Close | 539.89 | Low | 523.92 | High | 543.78 | Mkt Cap | 12.14B |
| Vol | 141.06K | Avg Vol | 349.80K | EPS | -13.50 | P/E | N/A | Forward P/E | 41.91 |
| Beta | -1.04 | Short Ratio | 13.25 | Inst. Own | 103.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 497.46 | 200-d Avg | 478.42 | 1yr Est | 674.36 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-06 | 2026-03 | 0 | N/A | 0.36 | 9.97% |
| 2026-02-19 | 2025-12 | 0.04 | N/A | -2.61 | -6.00% |
| 2025-11-04 | 2025-09 | 0 | N/A | -3.1 | -156.57% |
| 2025-08-05 | 2025-06 | 0 | N/A | 1.58 | 45.40% |
| 2025-05-01 | 2025-03 | 0 | N/A | 0.3 | 8.29% |
| 2025-02-26 | 2024-12 | 0 | N/A | 1.41 | 34.22% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-13 | Truist Securities | Upgrade | Buy | Buy |
| 2026-05-07 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-05-07 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-02-20 | B of A Securities | Upgrade | Neutral | Neutral |
| 2026-01-28 | Barclays | Upgrade | Overweight |
Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-08-19 | BAKER BROS ADVISORS, L.P. | Unknown | 0.00 | Purchase |
| 2025-03-12 | CRAVES FREDERICK B | Director | 383.55K | Sale |
| 2026-03-05 | DIER MARDI C | Chief Financial Officer | 12.49K | Sale |
| 2026-01-08 | FRIEDMAN PAUL A | Director | 842.70K | Sale |
| 2026-03-05 | HUNTSMAN CAROLE A | Officer | 12.69K | Sale |
| 2026-03-05 | KELLEY SHANNON T | General Counsel | 12.14K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Baker Bros. Advisors, LP | 2.14M | 1.16B | 9.29% |
| 2025-12-30 | RTW Investments LP | 1.99M | 1.08B | 8.65% |
| 2025-12-30 | Avoro Capital Advisors LLC | 1.81M | 975.85M | 7.84% |
| 2025-12-30 | PAULSON & CO. INC. | 1.71M | 921.87M | 7.41% |
| 2025-12-30 | Janus Henderson Group PLC | 1.58M | 855.64M | 6.87% |
| 2026-03-30 | Blackrock Inc. | 1.56M | 842.21M | 6.77% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 574.39K | 310.11M | 2.49% |
| 2026-03-30 | JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 429.42K | 231.84M | 1.86% |
| 2026-03-30 | iShares Trust-iShares Russell 2000 ETF | 414.60K | 223.84M | 1.80% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 412.29K | 222.59M | 1.79% |
| 2026-01-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 398.13K | 214.95M | 1.73% |
| 2026-03-30 | JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 233.27K | 125.94M | 1.01% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2016-07-25 |
